Sublocade/buprenorphine Cost, Side effects, Dosage, Uses Opioid use disorder

Sublocade/buprenorphine Cost, Side effects, Dosage, Uses Opioid use disorder. The FDA granted the approval of Sublocade to Indivior Inc.

US FDA approved drug Sublocade that contains buprenorphine as a active pharmaceutical ingredient for the treatment of moderate to severe opioid use disorder (OUD) in adult patients. This is the first once monthly injectable buprenorphine product. Availability of this drug is restricted to those pharmacies or hospital who are certified in REMS Program.

Opioid use disorder (OUD) is a condition that is directly related to  opioid use that causes clinically significant impairment or distress. Symptoms of opioid use disorder are strong desire to use opioids, enhanced tolerance rate and withdrawal syndrome in case opioids are abruptly stopped to administer. These symptoms may become severe if patient is misusing or overdosing opioids for longer period of time.

Opioids are basically medicinal products that are derived from synthetic or semi-synthetic sources for the relieving intense pain like trauma pain, Injuries, post operative pain or cancer pain. Supply of these products are kept under restriction due to their possible misuses or overdosing. Nalaxone is another important therapeutic drug used in case of opiod overdosing.

Sublocade Injection contains buprenorphine. Buprenorphine is a partial agonist at the mu receptor and antagonist at the kappa opioid receptor.

Sublocadebuprenorphine Cost, Side effects, Dosage, Uses Opioid use disorder

Sublocade/buprenorphine Side effects


Following side effects can be expected during the course of administration of this drug.

  • Nausea
  • Vomiting
  • Pain at injection site
  • Hypersensitivity
  • Rashes on skin
  • Fluctuation in the level of liver enzymes
  • Pruritis
  • Sleep disturbance

Sublocade/buprenorphine Uses/Prescribing Information


US FDA approved Sublocade for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosa buprenorphine containing product, followed by dose adjustment for a minimum of 7 days.

Sublocade/buprenorphine Dosage


Subcloade is injected in the abdominal area. Standard dosage frequency of Sublocade is 300 mg followed by 100 mg monthly maintenance doses. Maintenance doses might be increase depending upon the response rate and tolerance level of patient.

Sublocade/buprenorphine Cost


Sublocade/buprenorphine cost is difficult to evaluate at the moment as according to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Ogivri/trastuzumab-dkst Cost, Side effects, Dosage, Uses for Certain Cancers

Ogivri/trastuzumab-dkst Cost, Side effects, Dosage, Uses for Certain Cancers. The FDA granted approval of Ogivri to Mylan GmbH. Herceptin was approved in September 1998 and is manufactured by Genentech, Inc.

US FDA approved new drug Ogivri that is a a biosimilar to Herceptin (trastuzumab) for the treatment of certain kind of metastatic cancers like metastatic breast cancer or metastatic stomach cancer. A biosimilar product is a pharmaceutical product that is similar to a reference product which already been approved by the US FDA and has no therapeutic differences in terms of safety, purity and potency.

Stomach cancer is also termed as gastric cancer. Early signs ans symptoms of stomach cancers are weight loss, loss of appetite, nausea and vomiting. In later stages patient may feel difficulty in swallowing and have blood in stool. Pain in upper abdominal area may also be a symptoms of gastric metastasis. In later stages it becomes difficult to treat stomach cancer because it spreads to other areas like bones, lungs, liver.

Breast cancer is one of the leading cause of death in females due to cancer. Initially, it appears as a lump inside the breast that growth with the passage of time and reaches to progressive metastatic stage. There are no obvious symptoms at initial stages that makes it hard to diagnose earlier. Later on patient may feel bone pain, swollen lymph nodes, fatigue, shortness of breath and mild fever in some cases also been reported.

This drug encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Trastuzumab products have been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2.

Ogivritrastuzumab-dkst Cost, Side effects, Dosage, Uses for Certain Cancers


Ogivri/trastuzumab-dkst Side effects


Following side effects were observed during clinical trials of this drug.

  • Headache
  • Nausea
  • Vomiting
  • Mild fever
  • Weakness
  • Rashes on body
  • Less white blood cells count
  • Less red blood cells count
  • Abdominal discomfort
  • Pain in abdomen
  • Edema like condition
  • Hypersensitivity
  • Changes in taste sensation


Ogivri/trastuzumab-dkst Uses/Prescribing Information


Ogivri/trastuzumab-dkst is a a biosimilar to Herceptin (trastuzumab) for the treatment of certain kind of metastatic cancers like metastatic breast cancer or metastatic stomach cancer. According to data provided by health authorities this drug should be avoided in pregnancy due to fetal abnormalities.

Ogivri/trastuzumab-dkst Dosage


This drug is administered via intravenous route.

It is dosage frequency is 4 mg/kg as a 90 minute IV infusion followed by subsequent weekly doses of  2 mg/kg as 30 minute IV infusions in case of Metastatic HER2-Overexpressing Breast Cancer.

Initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks in case of Metastatic HER2-Overexpressing Gastric Cancer.


Ogivri/trastuzumab-dkst Cost


Ogivri/trastuzumab-dkst cost is difficult to evaluate at the moment as according to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Fasenra/benralizumab Cost, Side effects, Dosage, Uses for severe asthma

Fasenra/benralizumab Cost, Side effects, Dosage, Uses for severe asthma. US FDA granted approval of  Fasenra to AstraZeneca Pharmaceuticals.

US FDA approved new drug Fasenra that contains active pharmaceutical ingredient benralizumab which is monoclonal antibody for the treatment of  patients with severe asthma having  eosinophilic phenotype. US FDA approved this drug as add-on maintenance therapy in the treatment of severe
asthma. US FDA also instructed about this drug usage limitation means that it is not for treatment of other eosinophilic conditions or for relief of acute bronchospasm or status asthmaticus.

Asthma is a chronic disease that causes inflammation in the airways of the lungs. During an asthma attack, airways become narrow making it hard to breathe. Severe asthma attacks can lead to asthma-related hospitalizations because these attacks can be serious and even life-threatening.

According to the Centers for Disease Control and Prevention, as of 2013, more than 22 million people in the U.S. have asthma, and there are more than 400,000 asthma-related hospitalizations each year.

Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM. The IL-5 receptor is expressed on the surface of eosinophils and basophils. In an in vitro setting, the absence of fucose in the Fc domain of benralizumab facilitates binding (45.5 nM) to FcɣRIII receptors on immune effectors cells, such as natural killer (NK) cells, leading to apoptosis of eosinophils and basophils through antibody-dependent cell-mediated cytotoxicity (ADCC).


Fasenrabenralizumab Cost, Side effects, Dosage, Uses for severe asthma


Fasenra/benralizumab Side effects


Following side effects were observed during clinical trials of this drug


  • Headache
  • Hypersensitivity
  • Anaphylaxis
  • Pharyngitis
  • Rashes
  • Urticaria
  • Angioedema
  • Skin irritability

Fasenra/benralizumab Uses/Prescribing Information


This drug is approved for the treatment of  patients with severe asthma having  eosinophilic phenotype. US FDA approved this drug as add-on maintenance therapy in the treatment of severe
asthma. US FDA also instructed about this drug usage limitation means that it is not for treatment of other eosinophilic conditions or for relief of acute bronchospasm or status asthmaticus.

Fasenra/benralizumab Dosage


This drug is formulated in a single-dose prefilled syringe with potency of 30 mg/mL solution. Recommended dose is 30 mg every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter via subcutaneous injection.

Fasenra/benralizumab Cost


Fasenra/benralizumab cost is difficult to evaluate at the moment as according to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Mepsevii/vestronidase alfa-vjbk Cost, Side effects, Dosage, Uses for genetic enzyme disorder

Mepsevii/vestronidase alfa-vjbk Cost, Side effects, Dosage, Uses for genetic enzyme disorder.  The FDA granted approval of Mepsevii to Ultragenyx Pharmaceutical, Inc.

US FDA approved new drug Mepsevii that contains active pharmaceutical ingredient vestronidase alfa-vjbk for the treatment of metabolic disorder called as mucopolysaccharidosis type VII (MPS VII) which also described as Sly syndrome. This drug can be used in both adult as well as pediatric patients. Though, mucopolysaccharidosis type VII is rare kind of genetic disorder but it is progressively affects body tissues and organs.

Mucopolysaccharidosis Type VII or Sly syndrome is genetically induced disease characterized as deficiency of enzyme β-glucuronidase. Due to deficiency of this enzyme deposition of complex carbohydrates e.g mucopolysaccharides occur inside the tissues and organs of the body that's why it is termed as Mucopolysaccharidosis Type VII. It is basically an autosomal recessive lysosomal storage disease. It also named after an American biochemist William S. Sly who first described this disease (Sly syndrome).

Most commonly observed symptoms associated with Mucopolysaccharidosis Type VII or MPS include macrocephaly, corneal opacity, anteverted nostrils, cleft palate, kyphosis or hook like deformity in thoracic area. In severe cases pulmonary infection, spleen enlargement  and liver enlargement may occur. In newborn, this may cause growth retardation and affect motor functions of body.

Mepsevii is an enzyme replacement therapy that works by replacing the missing enzyme due to which accumulation of complex carbohydrates reduce to a great extent and patient also gets relief in severity of symptoms.

Mepseviivestronidase alfa-vjbk Cost, Side effects, Dosage, Uses for genetic enzyme disorder


Mepsevii/vestronidase alfa-vjbk Side effects


Following side effects were observed during clinical trail of this drug 
  • Diarrhea
  • Rashes on skin
  • Anaphylaxis
  • Reaction at injection site
  • Palpitation
  • Headache
  • Skin irritation


Mepsevii/vestronidase alfa-vjbk Uses/Prescribing Information


US FDA approved this drug for the treatment of rare genetic disorder mucopolysaccharidosis type VII (MPS VII) for both adults and child. This drug is an enzyme replacement therapy that works by replacing the missing enzyme.

Mepsevii/vestronidase alfa-vjbk Dosage


This drug is formulated in parenteral dosage form with potency of 2mg/mL (10mg/5mL single-dose vial). According to health authorities it is recommended that administer injection of any non-sedating antihistamine one hour before injecting Mepsevii to reduce the risk of reaction or hypersensitivity.

Mepsevii/vestronidase alfa-vjbk Cost


Mepsevii/vestronidase alfa-vjbk cost is difficult to evaluate at the moment as according to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Hemlibra/emicizumab-kxwh Cost, Side effects, Dosage, Uses for hemophilia A

Hemlibra/emicizumab-kxwh Cost, Side effects, Dosage, Uses for hemophilia A. The FDA granted the approval of Hemlibra to Genentech, Inc.

US FDA approved new drug Hemlibra that contains active pharmaceutical ingredient emicizumab-kxwh to decrease the tendency of bleeding episodes in patients with hemophilia A. This drug can be used in both adult patients and pediatric patients as well. Hemlibra/emicizumab-kxwh is a kind of monoclonal antibody administered via subcutaneous injection.  US FDA also instructed about some warnings associated with this drug if use in combination with activated prothrombin complex concentrate (aPCC).

Hemophilia A is a kind of genetic disorder characterized by deficiency of clotting factor VIII due to which tendency of bleeding increases many folds. Males are more affected by this disorder. Symptom of this disorder include frequent bleeding episodes followed by internal and external hemorrhaging from various sites like joints, gums, brain, digestive tract and muscles.

Hemophilia A is inherited as an X-linked recessive trait that most commonly affect males as compared to females. In females this disease occurs only if mother is carrier and father is a hemophiliac male. All kind of therapies are aimed to reduce the episodes of bleeding but there is no single treatment that can cure this disease permanently.

Mechanism of action by which Hemlibra/emicizumab-kxwh works is that it bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis. It is formulated in parenteral dosage form and is administered via subcutaneous route.  

Hemlibra/emicizumab-kxwh Cost, Side effects, Dosage, Uses for hemophilia A


Hemlibra/emicizumab-kxwh Side effects


Following side effects were observed during clinical trials of this drug

  • Headache
  • Pain in Joint
  • Reaction of site of injection
  • Asthenia
  • Mild rashes
  • palpitations
  • Hypersensitivity to drug


Hemlibra/emicizumab-kxwh Uses/Prescribing Information


US FDA indicated this drug to prevent or reduce the episodes of bleeding in patient with hemophilia A. There is not enough data available about its usage in pregnancy or lactation. However, US FDA warned about its usage with activated prothrombin complex concentrate (aPCC).

Hemlibra/emicizumab-kxwh Dosage


It is formulated in parenteral dosage form and its standard dosage frequency is 3 mg/kg by subcutaneous injection once weekly for the first 4 weeks, followed by 1.5 mg/kg once weekly. This drug will be available in following strength 30mg/ml, 60mg/0.4ml, 105mg/0.7ml and 150mg/ml in a single dose vial.

Hemlibra/emicizumab-kxwh Cost


Hemlibra/emicizumab-kxwh cost is difficult to evaluate at the moment as according to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Prevymis/Letermovir Cost, Side effects, Dosage, Uses for Cytomegalovirus (CMV) Infection

Prevymis/Letermovir Cost, Side effects, Dosage, Uses for Cytomegalovirus (CMV) Infection.

US FDA approved new drug Prevymis that contains Letermovir as an active pharmaceutical ingredient for the prophylaxis and treatment of infection caused by virus known as cytomegalovirus (CMV) in adult patients. US FDA also indicated this drug for the treatment of viral infection occurs after allogeneic hematopoietic stem cell transplant (HSCT). This drug will be available in two dosage form one is oral dosage form (Tablets) and second is parenteral dosage form (Injection) with potency of 240mg and 480mg.

Cytomegalovirus (CMV) belongs to a group of viruses known as Herpesviridae. It is known by the the name of human herpesvirus 5. Cytomegalovirus may cause infection at any site inside the human body but most commonly infect salivary glands. This virus may remain dormant in a human body until patient becomes immunocompromised. Cytomegalovirus (CMV) spreads rapidly inside the human body in case of weak immune system specifically in conditions like HIV infection, organ transplant and newly born infant. 

Most commonly observed problems with such viral infection are liver damage (liver necrosis), retinitis, colitis, pneumonitis, esophagitis, pyloradiculopathy etc. These problems may become worse with weak immune system or immunocompromised adults. This kind of viral infection is more common in developing countries with lower socioeconomic status.

Prevymis/Letermovir belongs to a class of anti-viral drugs. It works by inhibiting the CMV DNA terminase complex which is required for viral DNA processing and packaging. US FDA also indicated this drug for prophylactic treatment of infection occurs after stem cell transplant.

PrevymisLetermovir Cost, Side effects, Dosage, Uses for Cytomegalovirus (CMV) Infection


Prevymis/Letermovir Side effects


Following side effects were observed during clinical trails of this drug.

  • Nausea
  • Vomiting
  • Diarrhea
  • Edema like condition
  • Dry Cough 
  • Weakness
  • Rashes
  • Headache
  • Abdominal discomfort
  • Skin irritation
  • Hypersensitivity Reactions

Prevymis/Letermovir Uses/Prescribing Information


US FDA approved this drug for the treatment of infection caused by virus known as cytomegalovirus (CMV) in adult patients or prophylactic treatment of infection occurs after stem cell transplant. This drug must not be used with any immunosuppressant drug or ergot alkaloids.

Prevymis/Letermovir Dosage


Standard dosage frequency of Prevymis/Letermovir is 480mg orally (PO) once a day or intravenously via infusion over 1 hour through 100 days post-transplant. Dose adjustment must be kept under consideration in case of intolerance, toxicity renal or hepatic impairment.

Prevymis/Letermovir Cost


Prevymis/Letermovir cost is difficult to evaluate at the moment as according to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug.

Calquence/acalabrutinib Cost, Side effects, Dosage, Uses for Mantle cell lymphoma

Calquence/acalabrutinib Cost, Side effects, Dosage, Uses for Mantle cell lymphoma. The FDA granted the accelerated approval of Calquence to AstraZeneca Pharmaceuticals LP. US FDA approved new drug Calquence that contains acalabrutinib for the treatment of mantle cell lymphoma in adult patients who are not responding to prior therapy. US FDA granted accelerated approval of this medicine based on results received from single arm trial.

Mantle cell lymphoma (MCL) is a kind of non-Hodgkin's lymphoma and accounts for 6% of non-Hodgkin's lymphoma. Some commonly observed symptoms of Mantle cell lymphoma are extreme weight loss, mild fever, fatigue, lymph nodes enlargement, lumps in the body, sweating at night time. Enlarged spleen is another common finding during ultrasound in case of Mantle cell lymphoma. You health care provider may ask you for biopsy for further analysis of disease.

Exact underlying cause of Mantle cell lymphoma is not fully understood but many scientist assume that combination of factors like genetic predisposition, environmental factors, old age, alcoholism and sedentary lifestyle are important in the pathogenesis of Mantle cell lymphoma. Life expectancy and survival rate of mantle cell lymphoma heavily depends upon

Calquence/acalabrutinib is based on novel drug delivery system. This drug belongs to a class known as Bruton's tyrosine kinase (BTK) inhibitor. It is more potent in efficacy and has less side effects as compared other agents that belongs to bruton's tyrosine kinase (BTK) inhibitor class like ibrutinib. Main mechanism by which it restricts the proliferation of cancer cells is by blocking an enzyme needed by the cancer to multiply and spread.

Calquenceacalabrutinib Cost, Side effects, Dosage, Uses for Mantle cell lymphoma


Calquence/acalabrutinib Side effects


According to health authorities following side effects were observed during clinical trails of this drug.


  • Generalized weakness
  • Fatigue
  • Headche
  • Swelling
  • Brusing
  • Low red blood cells count
  • Low platelets count
  • Mild fever
  • Diarrhea
  • Skin irritation

Calquence/acalabrutinib Uses/Prescribing Information


US FDA approved this drug for the treatment of Mantle cell lymphoma in adult patients who are not responding to conventional therapy. On the basis of initial data received from clinical trials this drug should be avoided in pregnancy and breastfeeding.


Calquence/acalabrutinib Dosage


Recommended dose is 100 mg orally approximately every twelve hours. Swallow whole capsule with water and with or without food. Do not chew or break the capsule because it may cause drug loss or reduce the efficacy of drug. Dose titration must be consider in case of toxicity or other unexpected side effect that can not be tolerated.

Calquence/acalabrutinib Cost


Calquence/acalabrutinib is now available at retail outlets with average cost of 7300$ - 7400$ per pack that contains 30 capsules each with potency of 100mg. This cost may variate with the passage of time so, make it confirm by visiting your nearby pharmacy before purchasing.

Yescarta/axicabtagene Cost, Side effects, Dosage, Uses for B-cell lymphoma

Yescarta/axicabtagene Cost, Side effects, Dosage, Uses for B-cell lymphoma. The FDA granted approval of Yescarta to Kite Pharma, Inc.

US FDA approved second gene therapy product Yescarta that contains axicabtagene ciloleucel as an active pharmaceutical ingredient. It is basically cell based gene therapy that is used to target certain types of B-cell lymphoma in patients who are not responding to traditional therapy. FDA also indicated this drug in case of relapsed after using at least two other kinds of treatment.

B-cell lymphoma is a kind of blood cancer that affects lymph nodes. Lymphoma is more common in people who are immunocompromised and in older adults. They usually are of two types slow growing and rapidly growing lymphomas. Life expectancy and survival rate mainly depends upon stage, specific type and over all health of individual. Early detection is the key factor in the detection of such kind of cancers. Main components of treatment include chemotherapy and radiations. Symptoms of B-cell lymphoma are not so obvious in early stage or patients neglect them due to insignificant severity.

Yescarta/axicabtagene ciloleucel is targeted therapy to treat b-cell lymphoma but it is also associated with some risk factors like cytokines release syndrome so, US FDA instructed its usage in hospitals be certified for its use. Yescarta/axicabtagene is categorized as chimeric antigen receptor (CAR) T cell therapy that is approved by US FDA for various types of non-Hodgkin lymphoma.


Yescartaaxicabtagene Cost, Side effects, Dosage, Uses for B-cell lymphoma


Yescarta/axicabtagene Side effects


Following side effects were observed during clinical trials of Yescarta.

  • Cytokine release syndrome (Boxed warning)
  • High grade fever
  • Flu like symptoms
  • Toxicity
  • Neurlogical disturbance
  • Anaphylaxis
  • Reaction at site of injection
  • Sleeping problems
  • Asthenia
  • Body pain

Yescarta/axicabtagene Uses/Prescribing Information



US FDA approved this therapy for the treatment of certain kind of non-Hodgkin lymphomas that are not responding to traditional chemotherapy or relapsed after usage of at least two chemotherapeutic drugs. This therapy has potential risk of cytokine release syndrome so, US FDA indicated its usage in certified hospitals.

Yescarta/axicabtagene Dosage


Yescarta/axicabtagene is formulated as Single-dose units contain specific amounts of T cells depending on the patient’s body weight that are suspended in a patient-specific infusion bag. Target dose is 2 x 10^6 CAR-positive viable T cells/kg body weight.

Yescarta/axicabtagene Cost


Yescarta/axicabtagene cost is difficult to evaluate at the moment as according to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug.

Verzenio/abemaciclib Cost, Side effects, Dosage, Uses for certain advance Cancers

Verzenio/abemaciclib Cost, Side effects, Dosage, Uses for certain advance Cancers.The FDA granted the approval of Verzenio to Eli Lilly and Company.

US FDA approved new drug Verzenio that contains active pharmaceutical ingredient abemaciclib for the treatment of certain advance metastatic cancers like hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer. US FDA approved this in combination with other drug fulvestrant if there is not adequate response after administering endocrine therapy.

Though it is not first kind of therapy approved by US FDA that belongs to CDK inhibitors but according to US FDA statement this drug provides targeted  treatment option for certain patients with breast cancer who are not responding to treatment, and unlike other drugs in the class.

Breast cancer is one the highly prevailing cancer among women and spreads rapidly. Early detection of such kind of cancers is very important factor in defining prognosis, survival rate and life expectancy. Proper screening and following provided guidelines play important role in prevention and early detection of such disorders.

Verzenio/abemaciclib belongs to a class known as CDK inhibitors (cyclin dependent kinase inhibitors) but it specifically causes inhibition of CDK4 and CDK6. These molecules CDK4 and CDK6 play important role in the development of cancerous cells that's why their inhibition provides better control over disease
progression.

Verzenio/abemaciclib Cost, Side effects, Dosage, Uses for certain advance Cancers


Verzenio/abemaciclib Side effects


According to health authorities following side effects were observed during clinical trails

Common Side effects
  • Nausea
  • Vomiting
  • Abdominal Discomfort
  • Diarrhea
  • Weakness
  • Palpitations
  • Low white blood cell count
  • Loss of appetite
  • Headache
Serious or Severe side effects
  •  Elevated liver Enzymes
  • Clotting (Thrombosis)
  • Hypersentivity reaction
  • Anaphylaxis

Verzenio/abemaciclib Uses


Verzenio/abemaciclib is approved for the treatment of certain advance metastatic cancers like hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative advanced or metastatic breast cancer. US FDA approved this in combination with other drug fulvestrant if there is not adequate response after administering endocrine therapy.

Verzenio/abemaciclib Dosage


Verzenio/abemaciclib is formulated in tablet form for oral administration in following strength 50mg, 100mg, 150mg, 200mg. Recommended dosing frequency of Verzenio/abemaciclib is 200mg twice daily as mono therapy or 150mg twice daily in combination with fulvestrant.

Verzenio/abemaciclib Cost


Verzenio is now available at retail outlets with average cost of 6000$ - 6200$ per pack that contains 30 tablets each with potency of 150mg. This cost may variate with the passage of time so, make it confirm by visiting your nearby pharmacy before purchasing.

Mvasi Cost, Side effects, Dosage, Uses for Cancer

Mvasi Cost, Side effects, Dosage, Uses for cancer. The FDA granted approval of Mvasi to Amgen, Inc. Avastin was approved in February 2004 and is manufactured by Genentech, Inc.

US FDA approved first biosimilar drug Mvasi/bevacizumab-awwb for the treatment of different kind of cancers. Mvasi is quite equal in efficacy to already present reference product Avastin (Genetech/Roche) which was approved by US FDA in 2004. Mvasi has same indications like the reference product Avastin (Genetech/Roche). Mvasi/bevacizumab-awwb major indications include colon cancer, non-small cell lung cancer, glioblastoma, ovarian cancer, breast cancer and renal cell carcinoma. US FDA approved this biosmilar drug on the basis of cost difference because biosimilars are expected to be cheaper but their safety profile, indications and adverse effects are quite similar to reference product.

Cancer is one of the leading cause of death across the globe. Some tumors are not metastatic and less dangerous as compared to other metastatic cancers. Each cancer might have different sign and symptoms as compared to other one but as a general some commonly observed symptoms of cancer are consistent weight loss, sweating during night time, bleeding, formation of lumps, changes in bowel movements. Some kind of viral infections may also lead to cancer if persist for a longer period of time.

Rigorous research is still on the way to find complete cure of cancer. Etiology of each cancer might be different but certain risk factors like genetic predisposition, exposure to radiations and chemicals, chronic viral infections, sedentary life style, obesity, smoking, alcoholism and environmental pollution play important role in its development.

Mvasi Cost, Side effects, Dosage, Uses for Cancer


Mvasi Side effects


Some commonly observed side effects during this drug therapy include
  • Bleeding or hemorrhage
  • Hypertension
  • Nasal cavity swelling
  • Loss of protein through urine
  • Rashes
  • Changes in mouth taste
  • Nausea
  • Vomiting
  • Abdominal Discomfort
  • Dryness of skin
  • Excessive lacrimation
  • Skin allergy

Mvasi Uses


US FDA approved Mvasi for the treatment of Metastatic colorectal cancer in combination with other drugs or as second line therapy, non-squamous non-small cell lung cancer, glioblastoma in aggressive stage, metastatic renal cell carcinoma and cervical cancer.

Mvasi Dosage


Metastatic colorectal cancer
  • 5 mg/kg IV every 2 weeks with bolus-IFL
  • 10 mg/kg IV every 2 weeks with FOLFOX4
  • 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks with
fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin based chemotherapy after progression on a first-line bevacizumab product containing regimen.

Non-squamous non-small cell lung cancer 
  • 15 mg/kg IV every 3 weeks with carboplatin/paclitaxel
 Glioblastoma
  • 10 mg/kg IV every 2 weeks
Metastatic renal cell carcinoma (mRCC)
  • 10 mg/kg IV every 2 weeks with interferon alfa Persistent, recurrent, or metastatic carcinoma of the cervix
  • 15 mg/kg IV every 3 weeks with paclitaxel/cisplatin or paclitaxel/topotecan 

Mvasi Cost 


Mvasi cost is difficult to evaluate at the moment as according to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug.